Moderna is actively exploring partnerships in China even as its chief executive publicly warns that Beijing is pouring state resources into mRNA technology to challenge US dominance in the field, a tension that captures the balancing act many biotech firms now face.
CEO Stephane Bancel told Nikkei Asia that the company has “a number of ongoing discussions in greater China” about potential partnerships, as Moderna looks to expand beyond the COVID-19 vaccine business that built its reputation into treatments for cancer and other diseases in what he described as the world’s second-largest economy.
The outreach comes despite Bancel separately warning that while Washington has pulled back on mRNA funding, China’s government is investing heavily in the technology as part of a broader push to compete with the United States in biotechnology.
That dynamic puts Moderna in an unusual position: pursuing commercial access to one of the world's largest healthcare markets while simultaneously flagging that market's growing capacity to become a direct technological rival in the exact platform the company pioneered.
mRNA technology has increasingly been framed by officials on both sides as a strategic asset rather than purely a commercial one, with biotech platforms seen as relevant to both economic competitiveness and broader national security planning.
Moderna's pursuit of China partnerships despite that geopolitical backdrop suggests the company is betting that commercial opportunity in China outweighs the competitive risk of helping a potential rival's biotech ecosystem develop further, a bet that is likely to draw scrutiny from policymakers in Washington.
